Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Sensitivity analysis – reductions in mortality by 1 % per year for specified cancers

From: Projecting productivity losses for cancer-related mortality 2011 – 2030

Cancer Projected number of deaths Value of lost paid production (million €) Value of lost household production (million €) Projected number of deaths (% of base case) Value of lost paid production (million €) Value of lost household production (million €)
  Base case 1 % Annual reduction in mortality
C18-C21: colorectal 27,631 1321 6567 23,344 (84 %) 1169 5765
C25: pancreas 13,488 733 3355 11,673 (87 %) 649 2947
C34: lung 48,922 2403 12,493 41,730 (85 %) 2124 10,970
C50: breast 18,308 1255 7194 15,430 (84 %) 1113 6338
C70-C72: brain & CNS 6513 886 2164 5265 (81 %) 786 1907
C91-C95: leukaemia 6693 454 1691 5096 (76 %) 402 1486
C00-C96: all invasive 233,168 12,685 60,427 206,336 (89 %) 11,231 53,086